CEBPB and cancer: In this study, we have shown pharmacological activation of NRF2 by tBHQ, in turn increasing HER4 receptor at transcriptional and translational levels and increasing the survival of the cancer cells by reducing the cytotoxicity of the HER targeting chemotherapeutic drugs, LAP and ERL.